Advertisement covers IDWeek 2014


HIV Drug Development Pipeline Update, Fall 2014 Edition

November 11, 2014


HIV Drug Development Pipeline Update, Fall 2014 Edition

Some might say that the golden age of HIV drug development has come and gone. Those people might just be right.

But if there are fewer HIV antiretrovirals in the pipeline these days than there were in the late 1990s and much of the 2000s, it's with good reason: The drugs that made it through that grind transformed HIV treatment from a toxicity-filled, resistance-prone mountain of a pill burden into a highly manageable, tremendously effective intervention.

However, HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. At IDWeek 2014 in Philadelphia, Paul Sax, M.D., made the case for this new generation of drugs, and provided an update on several of the most noteworthy candidates currently in development.

get started

This article was provided by It is a part of the publication IDWeek 2014.

Reader Comments:

Comment by: What's wrong with this website? Thu., Nov. 13, 2014 at 1:36 pm UTC
We don't want more drugs, we want an effing cure!
Reply to this comment

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.